Leonid Zamora
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leonid Zamora has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Laniyati Hamijoyo
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
15 shared publications - Rangi Kandane-Rathnayake
Department of Medicine, Monash University, Clayton, Victoria, Australia
15 shared publications - Sandra Navarra
Section of Rheumatology, University of Santo Tomas Hospital , Manila
15 shared publications - Alberta Hoi
Department of Rheumatology Monash Health Melbourne Victoria Australia
14 shared publications - Chak Sing Lau
Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
14 shared publications - Eric Francis Morand
Department of Rheumatology, Monash Health, Clayton, Victoria, Australia
14 shared publications
Latest Publications
- 1 September 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Longitudinal Comparison of Treat-to-Target States and Clinical Outcomes in Patients With Late-Onset Versus Early-Onset Systemic Lupus Erythematosus
Objective: We compared demographic and clinical characteristics between patients with late-onset (LO) and early-onset (EO) systemic lupus erythematosus (SLE) and examined their longitudinal associations with treatment targets and long-term outcomes, irreversible organ damage accrual, and health-related quality of life (HRQOL). Methods: We analyzed prospectively collected data from patients enrolled in the Asia Pacific Lupus Collaboration cohort. Patients diagnosed with SLE at age > 50 years were classified as having LO-SLE, whereas those diagnosed at age ≤ 50 years were classified as having EO-SLE. Longitudinal associations with treatment targets (Low Lupus Disease Activity State [LLDAS] and Definition of Remission in SLE [DORIS] remission), organ damage accrual (Systemic Lupus International Collaborating Clinics/American College of Rheumatology [SLICC/ACR] Damage Index), and HRQOL (36-item Short Form Health Survey v2 physical and mental component summary [PCS and MCS] scores) were examined using multivariable multilevel logistic, recurrent event survival, and linear mixed-effects models, respectively. Disease activity, flares, medication exposure, and other clinical characteristics were also compared between groups. Results: Among 3917 patients studied, 346 (8.8%) had LO-SLE and 3571 (91.2%) had EO-SLE. Compared to patients with EO-SLE, those with LO-SLE had lower disease activity, lower glucocorticoid and immunosuppressant exposure, and higher attainment of treatment targets. LO-SLE was associated with higher odds of attaining LLDAS (odds ratio [OR] 2.33, 95% CI 1.66-3.28) and DORIS remission (OR 2.22, 95% CI 1.45-3.38). However, patients in this group were at a greater risk of damage accrual (hazard ratio 1.82, 95% CI 1.50-2.21) and lower PCS scores, meaning poorer physical health (regression coefficient [RC] −3.63, 95% CI −4.58 to −2.68), but not MCS scores (RC 0.68, 95% CI −0.50 to 1.86). Conclusion: Despite higher attainment of treatment targets, patients with LO-SLE experienced greater damage accrual and poorer physical health, suggesting that disease activity targets alone may not fully identify outcome risk in LO-SLE.
- 1 September 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Longitudinal Comparison of Treat-to-Target States and Clinical Outcomes in Patients With Late-Onset Versus Early-Onset Systemic Lupus Erythematosus
Objective: We compared demographic and clinical characteristics between patients with late-onset (LO) and early-onset (EO) systemic lupus erythematosus (SLE) and examined their longitudinal associations with treatment targets and long-term outcomes, irreversible organ damage accrual, and health-related quality of life (HRQOL). Methods: We analyzed prospectively collected data from patients enrolled in the Asia Pacific Lupus Collaboration cohort. Patients diagnosed with SLE at age > 50 years were classified as having LO-SLE, whereas those diagnosed at age ≤ 50 years were classified as having EO-SLE. Longitudinal associations with treatment targets (Low Lupus Disease Activity State [LLDAS] and Definition of Remission in SLE [DORIS] remission), organ damage accrual (Systemic Lupus International Collaborating Clinics/American College of Rheumatology [SLICC/ACR] Damage Index), and HRQOL (36-item Short Form Health Survey v2 physical and mental component summary [PCS and MCS] scores) were examined using multivariable multilevel logistic, recurrent event survival, and linear mixed-effects models, respectively. Disease activity, flares, medication exposure, and other clinical characteristics were also compared between groups. Results: Among 3917 patients studied, 346 (8.8%) had LO-SLE and 3571 (91.2%) had EO-SLE. Compared to patients with EO-SLE, those with LO-SLE had lower disease activity, lower glucocorticoid and immunosuppressant exposure, and higher attainment of treatment targets. LO-SLE was associated with higher odds of attaining LLDAS (odds ratio [OR] 2.33, 95% CI 1.66-3.28) and DORIS remission (OR 2.22, 95% CI 1.45-3.38). However, patients in this group were at a greater risk of damage accrual (hazard ratio 1.82, 95% CI 1.50-2.21) and lower PCS scores, meaning poorer physical health (regression coefficient [RC] −3.63, 95% CI −4.58 to −2.68), but not MCS scores (RC 0.68, 95% CI −0.50 to 1.86). Conclusion: Despite higher attainment of treatment targets, patients with LO-SLE experienced greater damage accrual and poorer physical health, suggesting that disease activity targets alone may not fully identify outcome risk in LO-SLE.
- Open Access
- 9 July 2026
- Published by Elsevier in SSRN Electronic Journal
Evaluation of Candidate Definitions of Severe Refractory Systemic Lupus Erythematosus Using Clinical Outcomes: Real-World Data Exploration Study
Background: Emerging advanced therapies are being trialled in patients with severe refractory systemic lupus erythematosus (srSLE), but this state lacks an evidence-based operational definition. We evaluated candidate srSLE definitions to determine which best identifies patients with poor outcomes.Methods: We constructed candidate srSLE definitions using varying thresholds of treatment-refractory disease activity and evaluated the definitions in the Asia Pacific Lupus Collaboration cohort. At each visit (tn), disease activity was defined using SLE Disease Activity Index (SLEDAI-2K ≥6, ≥8, ≥10, or ≥12), Physician Global Assessment (PGA ≥1 or >1), and SELENA-SLEDAI Flare Index (SFI mild-to-moderate and severe flare (MMSf) or severe flares only (Sf)). Treatment refractoriness required concurrent use of immunosuppressants (IS) at tn and tn-1 (preceding visit), together with glucocorticoids (GC, ≥5 or ≥10mg/day prednisolone equivalent), with or without concurrent anti-malarial (AM) use. Outcomes accessed at 12 months after the first visit fulfilling each definition criteria included flare, organ damage accrual (SLICC/ACR Damage Index) and non-attainment of lupus low disease activity state. Candidate definitions were ranked from highest to lowest rates for each outcome. Ten definitions were associated with highest rates across all three outcomes (‘top 10’); they were further evaluated using machine-learning–based gradient boosting models. Findings: We evaluated 80 candidate definitions (least stringent, achieved by 27% of patients, to most stringent, achieved by 1 and/or MMSf, while 4 definitions included exposure to triple therapy (GC+IS+AM). The best predictive performance on all three outcomes at 12-months was srSLE defined as SLEDAI≥6+GC≥10+IS+PGA>1+MMSf, observed in 267 (6.5%) of patients. Interpretation: We derived data-driven definitions of srSLE with strong predictive performance for poor patient outcomes. This may help standardise patient selection for trials of transformative therapies under development.
- 9 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEvaluation of Candidate Definitions of Severe Refractory Systemic Lupus Erythematosus Using Clinical Outcomes: Real-World Data Exploration Study
Background: Emerging advanced therapies are being trialled in patients with severe refractory systemic lupus erythematosus (srSLE), but this state lacks an evidence-based operational definition. We evaluated candidate srSLE definitions to determine which best identifies patients with poor outcomes.Methods: We constructed candidate srSLE definitions using varying thresholds of treatment-refractory disease activity and evaluated the definitions in the Asia Pacific Lupus Collaboration cohort. At each visit (tn), disease activity was defined using SLE Disease Activity Index (SLEDAI-2K ≥6, ≥8, ≥10, or ≥12), Physician Global Assessment (PGA ≥1 or >1), and SELENA-SLEDAI Flare Index (SFI mild-to-moderate and severe flare (MMSf) or severe flares only (Sf)). Treatment refractoriness required concurrent use of immunosuppressants (IS) at tn and tn-1 (preceding visit), together with glucocorticoids (GC, ≥5 or ≥10mg/day prednisolone equivalent), with or without concurrent anti-malarial (AM) use. Outcomes accessed at 12 months after the first visit fulfilling each definition criteria included flare, organ damage accrual (SLICC/ACR Damage Index) and non-attainment of lupus low disease activity state. Candidate definitions were ranked from highest to lowest rates for each outcome. Ten definitions were associated with highest rates across all three outcomes (‘top 10’); they were further evaluated using machine-learning–based gradient boosting models. Findings: We evaluated 80 candidate definitions (least stringent, achieved by 27% of patients, to most stringent, achieved by 1 and/or MMSf, while 4 definitions included exposure to triple therapy (GC+IS+AM). The best predictive performance on all three outcomes at 12-months was srSLE defined as SLEDAI≥6+GC≥10+IS+PGA>1+MMSf, observed in 267 (6.5%) of patients. Interpretation: We derived data-driven definitions of srSLE with strong predictive performance for poor patient outcomes. This may help standardise patient selection for trials of transformative therapies under development.
- Open Access
- 11 May 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Predictive correlates of arthritis and joint damage in systemic lupus erythematosus: a multinational prospective cohort study
Objectives: To determine the prevalence and predictive correlates of arthritis and joint damage in systemic lupus erythematosus (SLE) patients in the Asia-Pacific Lupus Collaboration (APLC) cohort, and to determine their impact on health-related quality of life (HRQoL). Methods: SLE patient data (2013–2020) were collected from the prospective multinational APLC cohort. We defined arthritis according to the SLE Disease Assessment Index (SLEDAI-2K) definition of persistent arthritis as arthritis in ≥2 consecutive visits, and joint damage according to the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) definition (deforming or erosive arthritis). HRQoL was measured by Short Form Survey (SF36). Descriptive statistics, univariable and multivariable Cox hazard models, and Kaplan–Meier analyses were performed. Results: During median 2.5 (1.0–5.1) years of follow-up, 803/4106 (19.6%) patients had arthritis at least once, and 18/3383 (0.53%) accrued joint damage. Patients with arthritis were more likely to be female, Caucasian, current smokers at enrolment, and less like to have tertiary education; they also had higher overall disease activity, and lower physical and mental HRQoL. Kaplan–Meier analysis demonstrated that joint damage was more likely in patients with arthritis. Persistent arthritis and longer follow-up were risk factors for joint damage accrual; being from high-income countries was protective. Patients with joint damage also had worse physical HRQoL. Conclusion: Arthritis in the APLC cohort was infrequent compared with other cohorts and was associated with smoking, higher overall disease activity, and damage accrual across multiple domains. Presence of arthritis significantly impacted physical and mental HRQoL. Joint damage was strongly predicted by persistent arthritis.
- 11 May 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Open AccessPredictive correlates of arthritis and joint damage in systemic lupus erythematosus: a multinational prospective cohort study
Objectives: To determine the prevalence and predictive correlates of arthritis and joint damage in systemic lupus erythematosus (SLE) patients in the Asia-Pacific Lupus Collaboration (APLC) cohort, and to determine their impact on health-related quality of life (HRQoL). Methods: SLE patient data (2013–2020) were collected from the prospective multinational APLC cohort. We defined arthritis according to the SLE Disease Assessment Index (SLEDAI-2K) definition of persistent arthritis as arthritis in ≥2 consecutive visits, and joint damage according to the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) definition (deforming or erosive arthritis). HRQoL was measured by Short Form Survey (SF36). Descriptive statistics, univariable and multivariable Cox hazard models, and Kaplan–Meier analyses were performed. Results: During median 2.5 (1.0–5.1) years of follow-up, 803/4106 (19.6%) patients had arthritis at least once, and 18/3383 (0.53%) accrued joint damage. Patients with arthritis were more likely to be female, Caucasian, current smokers at enrolment, and less like to have tertiary education; they also had higher overall disease activity, and lower physical and mental HRQoL. Kaplan–Meier analysis demonstrated that joint damage was more likely in patients with arthritis. Persistent arthritis and longer follow-up were risk factors for joint damage accrual; being from high-income countries was protective. Patients with joint damage also had worse physical HRQoL. Conclusion: Arthritis in the APLC cohort was infrequent compared with other cohorts and was associated with smoking, higher overall disease activity, and damage accrual across multiple domains. Presence of arthritis significantly impacted physical and mental HRQoL. Joint damage was strongly predicted by persistent arthritis.
- Open Access
- 18 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Predictors of damage accrual by organ domain in systemic lupus erythematosus
Objectives: Organ damage in SLE is assessed using the SLICC/ACR Damage Index (SDI), which quantifies damage in 12 organ systems but generally reports a total score. We examined whether the risk factors for overall organ damage accrual captured those associated with domain-specific damage accrual in patients with SLE. Methods: Data from a 13-country longitudinal SLE cohort were collected between 2013 and 2020 using standard templates. SDI was used to assess overall and domain-specific organ damage. A series of multi-failure, multivariate models were performed to examine the risk factors associated with overall and domain-specific damage accrual. Results: A total of 3449 patients with a median of 2.8 [interquartile range (IQR): 1.1, 5.6] years of follow-up were studied. Twenty-one percent (n = 717) patients accrued damage in at least one domain during the study period (musculoskeletal, 6%; renal and ocular, 5% each, neuropsychiatric, 2.5%; <2%, other domains). Risk factors for damage accrual differed among domains. Older age, cumulative glucocorticoid dose, existing skin damage, and diabetes were strong predictors in multiple but discrete domains. Asian ethnicity conferred greater risk of ocular, musculoskeletal, and diabetic damage accrual but was protective against peripheral vascular damage accrual. Smoking was a significant risk factor for peripheral vascular and skin damage accrual, while male sex was associated with the malignancy domain. Conclusion: Risk factors for individual organ system damage accrual were highly varied in patients with SLE. Not all factors associated with domain-specific damage accrual were captured by the risk factors analysed for overall organ damage accrual. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03138941.
- 18 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Open AccessPredictors of damage accrual by organ domain in systemic lupus erythematosus
Objectives: Organ damage in SLE is assessed using the SLICC/ACR Damage Index (SDI), which quantifies damage in 12 organ systems but generally reports a total score. We examined whether the risk factors for overall organ damage accrual captured those associated with domain-specific damage accrual in patients with SLE. Methods: Data from a 13-country longitudinal SLE cohort were collected between 2013 and 2020 using standard templates. SDI was used to assess overall and domain-specific organ damage. A series of multi-failure, multivariate models were performed to examine the risk factors associated with overall and domain-specific damage accrual. Results: A total of 3449 patients with a median of 2.8 [interquartile range (IQR): 1.1, 5.6] years of follow-up were studied. Twenty-one percent (n = 717) patients accrued damage in at least one domain during the study period (musculoskeletal, 6%; renal and ocular, 5% each, neuropsychiatric, 2.5%; <2%, other domains). Risk factors for damage accrual differed among domains. Older age, cumulative glucocorticoid dose, existing skin damage, and diabetes were strong predictors in multiple but discrete domains. Asian ethnicity conferred greater risk of ocular, musculoskeletal, and diabetic damage accrual but was protective against peripheral vascular damage accrual. Smoking was a significant risk factor for peripheral vascular and skin damage accrual, while male sex was associated with the malignancy domain. Conclusion: Risk factors for individual organ system damage accrual were highly varied in patients with SLE. Not all factors associated with domain-specific damage accrual were captured by the risk factors analysed for overall organ damage accrual. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03138941.
- Open Access
- 18 September 2024
- Published by BMJ in Lupus Science & Medicine
- Vol. 11 (2) , e001217
Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus
Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological activity only or neither clinical nor serological activity. Methods Patients with SLE enrolled in a prospective multinational cohort from March 2013 to December 2020 who were in LLDAS at least once were included. Visits that fulfilled both LLDAS and Definition of Remission in SLE (DORIS) criteria were excluded. Results 2099 patients were included, with median follow-up of 3.5 (IQR 1.3–5.8) years. At 6150 visits, patients were in LLDAS but not DORIS criteria; of these 1280 (20.8%) had some clinical activity, 3102 (50.4%) visits had serological activity only and 1768 (28.8%) visits had neither clinical nor serological activity. Multivariable regression analysis showed that compared with non-LLDAS, all three subsets of LLDAS had a protective association with flares in the ensuing 6 months and damage accrual in the ensuing 36 months. LLDAS with no clinical or serological activity had a significantly stronger protective association with severe flares in the ensuing 6 months compared with LLDAS with clinical activity (HR 0.47, 95% CI (0.27 to 0.82), p=0.007). Conclusions LLDAS without any clinical activity accounted for almost 80% of LLDAS visits. This study confirms that all subsets of LLDAS are associated with reduced flare and damage accrual. However, LLDAS without any clinical or serological activity has the strongest protective association with severe flares.
- 18 September 2024
- Published by BMJ in Lupus Science & Medicine
- Vol. 11 (2) , e001217
Open AccessCharacterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus
Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological activity only or neither clinical nor serological activity. Methods Patients with SLE enrolled in a prospective multinational cohort from March 2013 to December 2020 who were in LLDAS at least once were included. Visits that fulfilled both LLDAS and Definition of Remission in SLE (DORIS) criteria were excluded. Results 2099 patients were included, with median follow-up of 3.5 (IQR 1.3–5.8) years. At 6150 visits, patients were in LLDAS but not DORIS criteria; of these 1280 (20.8%) had some clinical activity, 3102 (50.4%) visits had serological activity only and 1768 (28.8%) visits had neither clinical nor serological activity. Multivariable regression analysis showed that compared with non-LLDAS, all three subsets of LLDAS had a protective association with flares in the ensuing 6 months and damage accrual in the ensuing 36 months. LLDAS with no clinical or serological activity had a significantly stronger protective association with severe flares in the ensuing 6 months compared with LLDAS with clinical activity (HR 0.47, 95% CI (0.27 to 0.82), p=0.007). Conclusions LLDAS without any clinical activity accounted for almost 80% of LLDAS visits. This study confirms that all subsets of LLDAS are associated with reduced flare and damage accrual. However, LLDAS without any clinical or serological activity has the strongest protective association with severe flares.
- Open Access
- 15 March 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (8) , 790-797
Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus
Objective: To assess whether Lupus Low Disease Activity State (LLDAS) attainment is associated with favorable outcomes in patients with recent onset systemic lupus erythematosus (SLE).Methods: Data from a 13-country longitudinal SLE cohort were collected prospectively between 2013 and 2020. An inception cohort was defined based on disease duration < 1 year at enrollment. Patient characteristics between inception and noninception cohorts were compared. Survival analyses were performed to examine the association between LLDAS attainment and damage accrual and flare.Results: Of the total 4106 patients, 680 (16.6%) were recruited within 1 year of SLE diagnosis (inception cohort). Compared to the noninception cohort, inception cohort patients were significantly younger, had higher disease activity, and used more glucocorticoids, but had less organ damage at enrollment. Significantly fewer inception cohort patients were in LLDAS at enrollment than the noninception cohort (29.6% vs 52.3%,P< 0.001), but three-quarters of both groups achieved LLDAS at least once during follow-up. Limiting analysis only to patients not in LLDAS at enrollment, inception cohort patients were 60% more likely to attain LLDAS (hazard ratio 1.37, 95% CI 1.16-1.61,P< 0.001) than noninception cohort patients and attained LLDAS significantly faster. LLDAS attainment was significantly protective against flare in both the inception and noninception cohorts. A total of 88 (13.6%) inception cohort patients accrued organ damage during a median 2.2 years of follow-up.Conclusion: LLDAS attainment is protective from flare in recent onset SLE. Significant protection from damage accrual was not observed because of low rates of damage accrual in the first years after SLE diagnosis. (ClinicalTrials.gov:NCT03138941)
- 15 March 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (8) , 790-797
Open AccessComparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus
Objective: To assess whether Lupus Low Disease Activity State (LLDAS) attainment is associated with favorable outcomes in patients with recent onset systemic lupus erythematosus (SLE).Methods: Data from a 13-country longitudinal SLE cohort were collected prospectively between 2013 and 2020. An inception cohort was defined based on disease duration < 1 year at enrollment. Patient characteristics between inception and noninception cohorts were compared. Survival analyses were performed to examine the association between LLDAS attainment and damage accrual and flare.Results: Of the total 4106 patients, 680 (16.6%) were recruited within 1 year of SLE diagnosis (inception cohort). Compared to the noninception cohort, inception cohort patients were significantly younger, had higher disease activity, and used more glucocorticoids, but had less organ damage at enrollment. Significantly fewer inception cohort patients were in LLDAS at enrollment than the noninception cohort (29.6% vs 52.3%,P< 0.001), but three-quarters of both groups achieved LLDAS at least once during follow-up. Limiting analysis only to patients not in LLDAS at enrollment, inception cohort patients were 60% more likely to attain LLDAS (hazard ratio 1.37, 95% CI 1.16-1.61,P< 0.001) than noninception cohort patients and attained LLDAS significantly faster. LLDAS attainment was significantly protective against flare in both the inception and noninception cohorts. A total of 88 (13.6%) inception cohort patients accrued organ damage during a median 2.2 years of follow-up.Conclusion: LLDAS attainment is protective from flare in recent onset SLE. Significant protection from damage accrual was not observed because of low rates of damage accrual in the first years after SLE diagnosis. (ClinicalTrials.gov:NCT03138941)
- 12 September 2023
- Published by Elsevier in The Lancet Rheumatology
- Vol. 5 (10) , e584-e593
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study
- 12 September 2023
- Published by Elsevier in The Lancet Rheumatology
- Vol. 5 (10) , e584-e593
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study
- Open Access
- 19 May 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (2) , 525-533
SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus—an analysis of anti-double-stranded DNA monitoring
Disease activity monitoring in SLE includes serial measurement of anti-double stranded-DNA (dsDNA) antibodies, but in patients who are persistently anti-dsDNA positive, the utility of repeated measurement is unclear. We investigated the usefulness of serial anti-dsDNA testing in predicting flare in SLE patients who are persistently anti-dsDNA positive. Data were analysed from patients in a multinational longitudinal cohort with known anti-dsDNA results from 2013 to 2021. Patients were categorized based on their anti-dsDNA results as persistently negative, fluctuating or persistently positive. Cox regression models were used to examine longitudinal associations of anti-dsDNA results with flare. Data from 37 582 visits of 3484 patients were analysed. Of the patients 1029 (29.5%) had persistently positive anti-dsDNA and 1195 (34.3%) had fluctuating results. Anti-dsDNA expressed as a ratio to the normal cut-off was associated with the risk of subsequent flare, including in the persistently positive cohort (adjusted hazard ratio [HR] 1.56; 95% CI: 1.30, 1.87; P < 0.001) and fluctuating cohort (adjusted HR 1.46; 95% CI: 1.28, 1.66), both for a ratio >3. Both increases and decreases in anti-dsDNA more than 2-fold compared with the previous visit were associated with increased risk of flare in the fluctuating cohort (adjusted HR 1.33; 95% CI: 1.08, 1.65; P = 0.008) and the persistently positive cohort (adjusted HR 1.36; 95% CI: 1.08, 1.71; P = 0.009). Absolute value and change in anti-dsDNA titres predict flares, including in persistently anti-dsDNA positive patients. This indicates that repeat monitoring of dsDNA has value in routine testing.
- 19 May 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (2) , 525-533
Open AccessSMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus—an analysis of anti-double-stranded DNA monitoring
Disease activity monitoring in SLE includes serial measurement of anti-double stranded-DNA (dsDNA) antibodies, but in patients who are persistently anti-dsDNA positive, the utility of repeated measurement is unclear. We investigated the usefulness of serial anti-dsDNA testing in predicting flare in SLE patients who are persistently anti-dsDNA positive. Data were analysed from patients in a multinational longitudinal cohort with known anti-dsDNA results from 2013 to 2021. Patients were categorized based on their anti-dsDNA results as persistently negative, fluctuating or persistently positive. Cox regression models were used to examine longitudinal associations of anti-dsDNA results with flare. Data from 37 582 visits of 3484 patients were analysed. Of the patients 1029 (29.5%) had persistently positive anti-dsDNA and 1195 (34.3%) had fluctuating results. Anti-dsDNA expressed as a ratio to the normal cut-off was associated with the risk of subsequent flare, including in the persistently positive cohort (adjusted hazard ratio [HR] 1.56; 95% CI: 1.30, 1.87; P < 0.001) and fluctuating cohort (adjusted HR 1.46; 95% CI: 1.28, 1.66), both for a ratio >3. Both increases and decreases in anti-dsDNA more than 2-fold compared with the previous visit were associated with increased risk of flare in the fluctuating cohort (adjusted HR 1.33; 95% CI: 1.08, 1.65; P = 0.008) and the persistently positive cohort (adjusted HR 1.36; 95% CI: 1.08, 1.71; P = 0.009). Absolute value and change in anti-dsDNA titres predict flares, including in persistently anti-dsDNA positive patients. This indicates that repeat monitoring of dsDNA has value in routine testing.
- 22 October 2022
- Published by Elsevier in The Lancet Rheumatology
- Vol. 4 (12) , e822-e830
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study
- 22 October 2022
- Published by Elsevier in The Lancet Rheumatology
- Vol. 4 (12) , e822-e830
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study
- Open Access
- 14 March 2022
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 24 (1) , 1-10
‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study
Background: The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to formally define unmet need in SLE. In this study, we enumerated the prevalence of these states and examined their association with adverse outcomes. Methods: Data were collected prospectively in a 13-country longitudinal SLE cohort between 2013 and 2019. Unmet need was defined as never attaining lupus low disease activity state (LLDAS), a time-adjusted mean SLEDAI-2K (AMS) > 4, or ever experiencing high disease activity status (HDAS; SLEDAI-2K ≥10). Health-related quality of life (HRQoL) was assessed using SF36 (v2) and damage accrual using the SLICC-ACR SLE Damage Index (SDI). Results: A total of 3384 SLE patients were followed over 30,313 visits (median [IQR] follow-up 2.4 [0.4, 4.3] years). Eight hundred thirteen patients (24%) never achieved LLDAS. Median AMS was 3.0 [1.4, 4.9]; 34% of patients had AMS > 4. Twenty-five per cent of patients had episodes of HDAS. Each of LLDAS-never, AMS>4, and HDAS-ever was strongly associated with damage accrual, higher glucocorticoid use, and worse HRQoL. Mortality was significantly increased in LLDAS-never (adjusted HR [95% CI] = 4.98 [2.07, 12.0], pCI] = 5.45 [2.75, 10.8], p<0.001) patients. Conclusion: Failure to achieve LLDAS, high average disease activity, and episodes of HDAS were prevalent in SLE and were significantly associated with poor outcomes including organ damage, glucocorticoid exposure, poor quality of life, and mortality.
- 14 March 2022
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 24 (1) , 1-10
Open Access‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study
Background: The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to formally define unmet need in SLE. In this study, we enumerated the prevalence of these states and examined their association with adverse outcomes. Methods: Data were collected prospectively in a 13-country longitudinal SLE cohort between 2013 and 2019. Unmet need was defined as never attaining lupus low disease activity state (LLDAS), a time-adjusted mean SLEDAI-2K (AMS) > 4, or ever experiencing high disease activity status (HDAS; SLEDAI-2K ≥10). Health-related quality of life (HRQoL) was assessed using SF36 (v2) and damage accrual using the SLICC-ACR SLE Damage Index (SDI). Results: A total of 3384 SLE patients were followed over 30,313 visits (median [IQR] follow-up 2.4 [0.4, 4.3] years). Eight hundred thirteen patients (24%) never achieved LLDAS. Median AMS was 3.0 [1.4, 4.9]; 34% of patients had AMS > 4. Twenty-five per cent of patients had episodes of HDAS. Each of LLDAS-never, AMS>4, and HDAS-ever was strongly associated with damage accrual, higher glucocorticoid use, and worse HRQoL. Mortality was significantly increased in LLDAS-never (adjusted HR [95% CI] = 4.98 [2.07, 12.0], pCI] = 5.45 [2.75, 10.8], p<0.001) patients. Conclusion: Failure to achieve LLDAS, high average disease activity, and episodes of HDAS were prevalent in SLE and were significantly associated with poor outcomes including organ damage, glucocorticoid exposure, poor quality of life, and mortality.